Physician profile
Gregory Pfister
NPI 1306161575
$522.86
in general payments reported to CMS, 2019-2025
10 companies · $17.38 in 2025
The $17.38 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.36 · 2022: $386 · 2023: $22.58 · 2025: $17.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.58 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.58 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $159.08 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $121.47 | 2021-2022 | |
| Glaxosmithkline, LLC. | $62.80 | 2021-2022 | |
| Grifols USA, LLC | $39.49 | 2022 | |
| Advanced Respiratory, INC | $34.25 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.97 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $22.58 | 2023 | Austedo Xr |
| Philips North America LLC | $18.53 | 2022 | |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Gilead Sciences, INC. | $17.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Pfister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.